Immunic, Inc. Reports Encouraging Q3 2025 Results and Future Milestones on Vidofludimus Calcium Immunic, Inc. released its Q3 2025 financial results, highlighting significant advancements in Vidofludimus Calcium for treating multiple sclerosis.

Immunic, Inc. Reports Encouraging Q3 2025 Results and Future Milestones on Vidofludimus Calcium #United_States #New_York #Immunic #Vidofludimus_Calcium #MS_Treatment